Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
NPC Blog
NPC Blog
2010 Archives
2009 Archives
2008 Archives
2007 Archives
2006 Archives
Search Archives
Archives
  • February 2010 (1)
  • January 2010 (1)
  • December 2009 (1)
  • November 2009 (1)
  • October 2009 (1)
  • September 2009 (2)
  • July 2009 (1)
  • April 2009 (1)
  • March 2009 (1)
  • February 2009 (1)
  • December 2008 (1)
  • October 2008 (1)
  • September 2008 (1)
  • August 2008 (2)
  • July 2008 (2)
  • June 2008 (4)
  • May 2008 (1)
  • April 2008 (1)
  • March 2008 (4)
  • February 2008 (1)
  • April 2007 (1)
  • December 2006 (1)
  • October 2006 (1)
  • September 2006 (1)
  • July 2006 (2)
  • June 2006 (3)
  •  

    Subscribe in a reader

    E-Alerts
    Signup to receive news and announcements from Nutra Pharma:
    First Name:
    Last Name:
    Email:
     
    Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

    NPC Blog

    A Quick Note about Recent Changes to our Patent Portfolio

    Several months ago we decided to let go of 18 patents that we had originally licensed from NanoLogix for use with our Designer Diagnostics test kit technology. We were no longer using these patents and they are not material to Nutra Pharma, so it did not make sense for us to continue paying hefty royalties to NanoLogix. Additionally, this decision allows us to free up additional cash that we can now put towards better use within the Company. Moving forward, we continue to own 11 patents that are important to developing our test kit technology as it applies to human and animal testing as well as environmental testing.


    SEC Disclaimer
    This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The article, "A Quick Note about Recent Changes to our Patent Portfolio", should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

    del.icio.us:A Quick Note about Recent Changes to our Patent Portfolio digg:A Quick Note about Recent Changes to our Patent Portfolio spurl:A Quick Note about Recent Changes to our Patent Portfolio wists:A Quick Note about Recent Changes to our Patent Portfolio simpy:A Quick Note about Recent Changes to our Patent Portfolio newsvine:A Quick Note about Recent Changes to our Patent Portfolio blinklist:A Quick Note about Recent Changes to our Patent Portfolio furl:A Quick Note about Recent Changes to our Patent Portfolio reddit:A Quick Note about Recent Changes to our Patent Portfolio fark:A Quick Note about Recent Changes to our Patent Portfolio blogmarks:A Quick Note about Recent Changes to our Patent Portfolio Y!:A Quick Note about Recent Changes to our Patent Portfolio smarking:A Quick Note about Recent Changes to our Patent Portfolio magnolia:A Quick Note about Recent Changes to our Patent Portfolio segnalo:A Quick Note about Recent Changes to our Patent Portfolio gifttagging:A Quick Note about Recent Changes to our Patent Portfolio


    Comments

    No comments yet.

    RSS feed for comments on this post.

    TrackBack URL


    Leave a Comment

     
    Quick Nav
    Cobroxin for Chronic Pain
    Nyloxin // Chronic Pain Relief

     

     
    Recent News
     
    February 02, 2010
    Nutra Pharma Announces Fourth Quarter Sales for its Over-the-Counter (OTC) Pain Reliever, Cobroxin


    January 14, 2010
    Nutra Pharma to Present and Exhibit at Upcoming Investment Conferences in Scottsdale, Arizona, and Orlando, Florida


     
     
    Announcements
    Click Here to read the Nutra Pharma blog post: "An Exciting Day for Nutra Pharma at the World MoneyShow".
     
     
    Facebook   Twitter
     
    NPC
    Privacy Policy Code of Ethics